VSTM Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.541

-59.32%

-0.560

-41.67%

-0.517

+32.48%

Estimates Revision

The market is revising Upward the revenue expectations for Verastem, Inc. (VSTM) for FY2025, with the revenue forecasts being adjusted by 69.25% over the past three months. During the same period, the stock price has changed by -15.69%.

Revenue Estimates for FY2025

Revise Upward

+69.25%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+20.78%

In Past 3 Month

Stock Price

Go Down

-15.69%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast VSTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VSTM is 15.50 USD with a low forecast of 14.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

14.00

Averages

15.50

High

20.00

Current: 0.000

Low

14.00

Averages

15.50

High

20.00

Guggenheim

Michael Schmidt

Buy

maintain

$14

2025-12-30

Reason

Guggenheim

Michael Schmidt

Price Target

$14

2025-12-30

maintain

Buy

Reason

After Verastem announced it will discontinue development of avutometinib/defactinib plus Amgen's (AMGN) sotorasib for KRAS G12C mutant NSCLC and end the RAMP 203 study, Guggenheim analyst Michael Schmidt tells investors that the firm is "not surprised by the announcement" given the RAMP 203 study and the KRAS G12Ci combo opportunity has not been a major investor focus or meaningful component of the stock's valuation. The firm maintains a Buy rating and $14 price target on Verastem shares.

Mizuho

Outperform

maintain

$15

2025-11-04

Reason

Mizuho

Price Target

$15

2025-11-04

maintain

Outperform

Reason

Mizuho reiterated an Outperform rating and $15 price target on Verastem, noting the shares are falling intraday following the company's Q3 results. At first blush, the firm was "thoroughly impressed" by the first full quarterly sales of lead asset Avmapki Fakzynja/AF Co-Pack of $11.2M, which came in handily ahead of the firm's and Bloomberg's consensus estimates. Mizuho said that it believes the stock weakness is related to two updates, namely a need to add 29 additional patients to the confirmatory Phase 3 RAMP 301 study for AF and uncertainty on the timing of AF's potential inclusion in updated National Comprehensive Cancer Network treatment guidelines. The firm added that the current weakness appears overdone and recommends being "opportunistic."

Mizuho

NULL -> Outperform

maintain

$14 -> $15

2025-10-29

Reason

Mizuho

Price Target

$14 -> $15

2025-10-29

maintain

NULL -> Outperform

Reason

Mizuho raised the firm's price target on Verastem to $15 from $14 and keeps an Outperform rating on the shares.

RBC Capital

Outperform

maintain

$13

2025-10-20

Reason

RBC Capital

Price Target

$13

2025-10-20

maintain

Outperform

Reason

RBC Capital keeps an Outperform rating on Verastem with a $13 price target after the company's partner GenFleet Therapeutics reported Phase I/II data for VS-7375 outside of China in advanced pancreatic ductal adenocarcinoma patients with a KRAS G12D mutation. The data show meaningful efficacy in a highly refractory patient population, the analyst tells investors in a research note. The firm says that while VS-7375's response rate of 41% "look best-in-class," they did did decrease somewhat from the prior readout. They data overall are "still impressive," contends RBC. Verastem shares in midday trading are down 13% to $8.01.

Cantor Fitzgerald

Eric Schmidt

Overweight

initiated

$15

2025-10-16

Reason

Cantor Fitzgerald

Eric Schmidt

Price Target

$15

2025-10-16

initiated

Overweight

Reason

Cantor Fitzgerald analyst Eric Schmidt assumed coverage of Verastem with an Overweight rating and no price target. The company is developing and commercializing drugs for Ras-driven cancers, the analyst tells investors in a research note. The firm thinks the shares are worth $15 based on a sum-of-the-parts valuation. The company's avutometinib and defactinib looks like a better and more tolerable drug than the MEK inhibitors that are used off-label in recurrent low-grade serous ovarian cancer, contends Cantor.

Leerink

Jonathan Chang

Outperform

maintain

2025-09-08

Reason

Leerink

Jonathan Chang

Price Target

2025-09-08

maintain

Outperform

Reason

Leerink analyst Jonathan Chang says that following Verastem (VSTM)/GenFleet's interim data presentation for their KRAS G12D inhibitor program, the firm continues to view Revolution Medicines' (RVMD) zoldonrasib as well-positioned in the competitive landscape. Leerink notes that Outperform-rated Revolution is evaluating zoldonrasib in several Phase I/II trials. Separately, the firm hosted a pulse call with a MEDACorp NSCLC key opinion leader that, among other topics, discussed this data readout and its readthrough to Revolution's programs. At a high level, its MEDACorp KOL was encouraged by the response rate shown by VS-7475/GFH375, but they also acknowledged the caveat that the number of patients reported in the study is still small, making it difficult to compare trials from this limited patient population. Taken together, Leerink sees this update as supportive of the KRAS G12D inhibitor class as a whole and as continuing to position zoldonrasib favorably within the competitive landscape in NSCLC.

Valuation Metrics

The current forward P/E ratio for Verastem Inc (VSTM.O) is -3.46, compared to its 5-year average forward P/E of -5.19. For a more detailed relative valuation and DCF analysis to assess Verastem Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.19

Current PE

-3.46

Overvalued PE

2.31

Undervalued PE

-12.68

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.17

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.42

Undervalued EV/EBITDA

-0.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

648.06

Current PS

6.71

Overvalued PS

2433.35

Undervalued PS

-1137.24

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 1120.13% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

VSTM News & Events

Events Timeline

No data

News

2.0

01-02Benzinga

Verastem Discontinues RAMP 203 Trial, Shifts Focus to VS-7375

8.5

2025-12-30Benzinga

TEN Holdings Inc. Raises $2.25M in Private Placement, Shares Surge 17%

9.0

2025-12-29Yahoo Finance

Verastem Discontinues RAMP 203 Clinical Trial for Treatment

People Also Watch

Frequently Asked Questions

What is Verastem Inc (VSTM) stock price today?

The current price of VSTM is 7.79 USD — it has decreased -1.02 % in the last trading day.

What is Verastem Inc (VSTM)'s business?

Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.

What is the price predicton of VSTM Stock?

What is Verastem Inc (VSTM)'s revenue for the last quarter?

Verastem Inc revenue for the last quarter amounts to 11.24M USD, decreased % YoY.

What is Verastem Inc (VSTM)'s earnings per share (EPS) for the last quarter?

Verastem Inc. EPS for the last quarter amounts to -1.35 USD, increased 125.00 % YoY.

What changes have occurred in the market's expectations for Verastem Inc (VSTM)'s fundamentals?

How many employees does Verastem Inc (VSTM). have?

Verastem Inc (VSTM) has 78 emplpoyees as of January 10 2026.

What is Verastem Inc (VSTM) market cap?

Today VSTM has the market capitalization of 586.74M USD.